Skip Header
Important information: The value of investments can go down as well as up so you may get back less than you invest. Investors should note that the views expressed may no longer be current and may have already been acted upon. This is a third-party news feed and may not reflect Fidelity’s views.

Anglo American books $1.9bn H1 loss, slashes divi as restructuring continues

(Sharecast News) - Anglo American on Thursday after the diversified miner reported a 180% increase in losses for the first half on the back of ongoing challenging conditions in the rough diamond market, leading the company to slash its interim dividend by 83%. Total losses including discontinued operations amounted to $1.88bn over the six months to 30 June, compared with a $672m loss the year before, with losses per share sinking to $1.58 from $0.55.

Interim results reflected negative earnings from discontinued operations and a lack of contribution from its struggling De Beers diamond operation.

The company last year announced plans to exit its diamond, steelmaking coal and nickel businesses - along with its platinum group metals division which was demerged in May - and instead focus on its core production of copper, iron ore, manganese ore and crop nutrients.

Steelmaking coal and nickel sales have now been agreed, while the sale of the De Beers diamond operation remains in process.

"We are delivering on our strategy, transforming Anglo American into a higher margin, more cash generative and more valuable mining company," said chief executive Duncan Wanblad.

Revenues totalled $8.95bn during the half, down 7% on the year before, while underlying EBITDA sank 20% to $2.96bn.

Meanwhile, the interim dividend was slashed to just $0.07 per share, down from $0.42 the year before though in line with the company's 40% payout policy.

The stock was down 1.4% at 2,200p by 0834 BST.

Share this article

Related Sharecast Articles

GSK gets preliminary nod for two respiratory drugs in Europe
(Sharecast News) - GSK said on Friday afternoon that two of its respiratory medicines had received positive opinions from the European Medicines Agency's Committee for Medicinal Products for Human Use, bringing the company closer to potential approvals across severe asthma, chronic rhinosinusitis with nasal polyps and chronic obstructive pulmonary disease.
Shore Capital hails improved US biotech funding environment for hVIVO
(Sharecast News) - Shares in AIM-listed hVIVO were continuing their recent surge on the back of encouraging signs from the US biotech market, which broker Shore Capital said has created a "much more favourable environment" for the company.
Weir to buy remaining 50% stake in Chile JV ESEL for £56m
(Sharecast News) - Weir said on Friday that it has agreed to buy the remaining 50% share of its Chile-based joint venture ESEL for a sterling equivalent purchase price of £56m.
Jefferies downgrades Whitbread, upgrades IHG
(Sharecast News) - Jefferies downgraded Whitbread to 'hold' from 'buy' on Friday as it applied the reverse upgrade to InterContinental Hotels.

Important information: This information is not a personal recommendation for any particular investment. If you are unsure about the suitability of an investment you should speak to one of Fidelity’s advisers or an authorised financial adviser of your choice. When you are thinking about investing in shares, it’s generally a good idea to consider holding them alongside other investments in a diversified portfolio of assets. Past performance is not a reliable indicator of future returns.

Award-winning online share dealing

Search, compare and select from thousands of shares.

Expert insights into investing your money

Our team of experts explore the world of share dealing.